New Swedish clinical study published in the British Journal of Dermatology demonstrates superiority of AI-algorithm guided melanoma diagnosis
Dermalyser AI-driven support tool achieved remarkable sensitivity and specificity values of 95% and 85%, respectively, with these figures increasing to 100% and 93% for invasive melanomas. Stockholm, Sweden, March 6, 2024. Results from a prospective, multicentre, clinical trial published today in the peer-reviewed British Journal of Dermatology showed that AI helps significantly improve melanoma detection rates. The trial was designed to evaluate Dermalyser, a smartphone-based diagnostic decision support system empowered by advanced artificial intelligence (AI) and was conducted in